A complete guide to the usage and dosage of bicizumab

As an innovative dual IL-17A and IL-17F inhibitor, Bimekizumab has gradually attracted clinical attention for its application in chronic immune-mediated diseases such as psoriasis and ankylosing spondylitis. Compared with traditional single-targeted biological agents, it shows a more effective therapeutic response in regulating immune activity and inflammatory factor release by simultaneously blocking two key inflammatory factor pathways. Standard usage and dosage have been gradually clarified in international guidelines and drug instructions, becoming an important reference for precise treatment.

Specifically, when used to treat plaque psoriasis, the recommended dose is 320mg each time by subcutaneous injection, once at 0, 4, 8, 12 and 16 weeks, which is the initial induction treatment stage. Thereafter, a maintenance phase is entered, usually administered every 8 weeks, to maintain efficacy and reduce the risk of relapse. For patients weighing 120 kg or more, taking into account differences in body surface area and drug distribution, the recommended frequency of maintenance treatment starting from week 16 is once every 4 weeks to ensure that drug concentrations are maintained at effective levels. This weight-related dosing strategy improves the science of personalized precision treatment. It is recommended to rotate the injection site to avoid skin irritation. The abdomen, thigh or outer upper arm is usually selected as the recommended area.

Since bichizumab has certain immunomodulatory functions, it is recommended to conduct infection screening before use. In particular, clear treatment strategies for chronic infections such as tuberculosis and hepatitis B are required. During the medication process, concomitant use with other powerful immunosuppressants should be avoided to prevent the risk of superimposed infection. Although its administration cycle is relatively long, patient compliance is significantly improved and the burden of frequent medical visits is also reduced. Current overseas clinical practice shows that its efficacy in the maintenance period is stable and can achieve long-term skin clearance goals for some patients.

In short, bicizumab provides an efficient and safe new way for long-term control of chronic inflammatory diseases through a fixed dose + weight adjustment mechanism, combined with a reasonable dosing cycle.

Reference materials:https://www.drugs.com/bimekizumab.html